Quidel Corp (QDEL) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and the year ended December 31, 2019.
Fourth Quarter 2019 Highlights
Total revenue increased 15% to $152.2 million, compared with $132.6 million in the fourth quarter of 2018. Cardiac Immunoassay revenue increased 5% to $65.8 million. Molecular Diagnostic Solutions revenue was $7.1 million, 21% growth from the fourth quarter of 2018. Influenza revenue increased 44% to $50.3 million, compared with $34.9 million in the fourth quarter of... More